Interferon-gamma therapy for infection control in chronic granulomatous disease. 1995

S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Interferon (IFN)-gamma was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection-associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O2- production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O2- generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN-gamma may be variably beneficial for infection control in CGD-patients, irrespective of the in vitro phagocyte functions. A longer follow-up time is needed to confirm the IFN response in CGD-patients.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007902 Length of Stay The period of confinement of a patient to a hospital or other health facility. Hospital Stay,Hospital Stays,Stay Length,Stay Lengths,Stay, Hospital,Stays, Hospital
D008297 Male Males
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006105 Granulomatous Disease, Chronic A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern. Autosomal Recessive Chronic Granulomatous Disease,Chronic Granulomatous Disease,Chronic Granulomatous Disease, Atypical,Chronic Granulomatous Disease, X-Linked,Cytochrome B-Negative Granulomatous Disease, Chronic, X-Linked,Cytochrome B-Positive Granulomatous Disease, Chronic, X-Linked,Granulomatous Disease, Chronic, X-Linked,Granulomatous Disease, Chronic, X-Linked, Variant,X-Linked Chronic Granulomatous Disease,Chronic Granulomatous Disease, X Linked,Chronic Granulomatous Diseases,Granulomatous Diseases, Chronic,X Linked Chronic Granulomatous Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
November 1991, The New England journal of medicine,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
March 1993, The Journal of infectious diseases,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
November 2008, Recent patents on anti-infective drug discovery,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
September 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
February 1991, Current opinion in immunology,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
April 1991, The Journal of infectious diseases,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
February 1991, The New England journal of medicine,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
January 1991, Reviews of infectious diseases,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
March 2003, Journal of the Formosan Medical Association = Taiwan yi zhi,
S Ohga, and J Okamura, and H Nakayama, and Y Nagatoshi, and K Ueda
January 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Copied contents to your clipboard!